The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Metastatic pheochromocytoma / paraganglioma (MPP) are rare while the prognosis was poor.
Penpulimab is specifically an immune check-point inhibitor of PD1 and has been approved for
the treatment of several malignancies.This phase II trial studies the efficacy and safety of
penpulimab in the treatment of MPP patients who fail to other systemic therapy.